Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer (HIPECStomach)
Sponsor: University Hospital Tuebingen
Terminated
Recruitment problems
Other terminated trials from University Hospital Tuebingen
This PHASE2/PHASE3 trial investigates Gastric Cancer and Peritoneal Carcinomatosis and is currently terminated or withdrawn. University Hospital Tuebingen leads this study, which shows 9 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2_PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Terminated PHASE2_PHASE3
Status: Recruiting → Terminated
-
Jan 2017 — Feb 2018 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Sep 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital Tuebingen
For direct contact, visit the study record on ClinicalTrials.gov .